Avalo Therapeutics, Inc.
HealthcareNASDAQ:AVTX · NASDAQ Capital Market
+$1.09 today
Vol 1.10M · Avg 1.57M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-94.2%
avg -823.4%
ROIC
-70.2%
avg -111.0%
ROA
-67.2%
avg -93.1%
Analysis
ROA is currently the strongest return metric at -67.2% versus its period average of -93.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Garry A. Neil | President, Chief Executive Officer & Director | $1.08M | — | 72 | $190,314.00 | 1.69% |
Mittie Doyle FACR | Chief Medical Officer | $750,128.00 | — | 61 | $51,776.00 | 0.46% |
Christopher Ryan Sullivan | Chief Financial Officer & Head of Investor relations | $629,400.00 | — | 42 | $40,773.00 | 0.36% |
Taylor Boyd | Chief Business Officer | $519,020.00 | — | 37 | $95,000.00 | 0.84% |
Barbara S. Slusher | Founder and Member of Scientific Advisory Board | — | — | 61 | — | — |
Solomon H. Snyder | Founder and Chairman of Scientific Advisory Board | — | — | 87 | — | — |
Paul C. Varki | Chief Legal Officer | — | — | 53 | $32,576.00 | 0.29% |
Dino C. Miano | Senior Vice President of CMC & Technical Operations | — | — | — | — | — |
Jennifer Riley | Chief Strategy Officer | — | — | 51 | $39,696.00 | 0.35% |
Ashley Ivanowicz | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
31
$6.43M
Net Sentiment
$6.43M
Net selling
Most Active
Sullivan Christopher Ryan
12 transactions
1–10 of 31
Analysis
Insiders reported 0 buys worth $0.00 and 31 sells worth $6.43M over the last 12 months. That adds up to net selling of $6.43M. Sullivan Christopher Ryan was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +38.9% (14yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +38.9% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Coherus Oncology, Inc.
NASDAQ:CHRS
$171.37M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages AVTX?
Avalo Therapeutics, Inc. (AVTX) lists 10 active executives. The top listed executive is Barbara S. Slusher, Founder and Member of Scientific Advisory Board.
Are AVTX insiders buying or selling?
Recent insider activity shows net buying of $31.79M.
Explore More
Continue the stock analysis
Jump to another research area for this company.